Document is current
Any future updates will be listed below
-
Authors
Gaujoux-Viala, Cécile https://orcid.org/0000-0002-2099-6496
Dernis, Emmanuelle https://orcid.org/0000-0001-6113-166X
Senbel, Eric https://orcid.org/0009-0001-6290-6110
Herman-Demars, Hélène https://orcid.org/0009-0000-3780-9418
Becker, Jennifer https://orcid.org/0009-0004-8554-4281
Flipo, René-Marc https://orcid.org/0000-0001-5528-8070
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05082805 at ClinicalTrials.govDocuments that mention this clinical trial
Methotrexate Maintenance After Initiation of Biological or Targeted Synthetic DMARDs in Rheumatoid Arthritis: Results from the 2-Year Longitudinal Prospective Non-interventional STRATEGE2 Study
https://doi.org/10.1007/s40744-025-00806-1
-
Funding
Funding for this research was provided by:
Nordic Pharma Group
- License Information
-
More Information
Article History
Received: 24 June 2025
Accepted: 15 October 2025
First Online: 3 December 2025
Declarations
:
: Cécile Gaujoux-Viala: AbbVie; Alfasigma; Amgen; Biocon; Biogen; Boehringer Ingelheim, Bristol-Myers Squibb; Celgene; Celltrion; Eli Lilly; Galapagos; Gilead Sciences; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; UCB Pharma and Viatrix. Emmanuelle Dernis: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Roche-Chugaï, Sandoz, Sanofi and UCB Pharma. Eric Senbel: Abbvie, Celltrion, Fresenius Kabi, Lilly, Medac, Nordic Pharma, Novartis, Pfizer, Sandoz and UCB. Hélène Herman-Demars and Jennifer Becker: employees Nordic Pharma France. René-Marc Flipo: Abbvie, Bristol-Myers Squibb, Eli-Lilly, Janssen, MSD, Nordic Pharma, Novartis, Pfizer, Roche-Chugaï, Sandoz and Sanofi.
: This study was approved on 12 November 2018, by an independent ethics committee (Comité de Protection des Personnes Sud Méditerranée V; Reference 18.068). All participating study sites accepted the single ethics committee approval. The ethics committee expressly authorized the use of oral non-opposition, as permitted for non-interventional research conducted in France and involving no risk or constraint beyond routine clinical practice. Participants received comprehensive written information about the study objectives, procedures, and their rights, in compliance with Articles L.1121-1 and L.1122-1-1 of the French Public Health Code. Oral non-opposition to the collection of their personal data was obtained prior to participant inclusion and documented in the study records, as required by local regulations governing non-interventional studies in France. All data were processed in compliance with the reference methodology MR-003 from the French Data Protection Authority (CNIL), ensuring the protection of participant privacy and data integrity.
